Third Time Lucky For GSK-Teva ‘Skinny Label’ Review?
AAM Weighs In As Part Of Bid For ‘En Banc’ Appeals Court Rehearing
An amicus brief filed by the AAM has backed Teva’s bid to have the US Court of Appeals for the Federal Circuit rehear litigation with GSK that revolves around skinny-label generics that carve out patented indications. But after a pair of controversial prior decisions in the originator’s favor, will the third time be the charm?
